Search results
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post...
Benzinga· 3 days agoToday AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth ...
AstraZeneca aims for $80 bln in total revenue by 2030
Reuters· 3 days ago, opens new tab aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday,...
AstraZeneca Targets $80B Revenue by 2030 Through Pipeline Expansion
Market Watch· 3 days agoBy Helena Smolak AstraZeneca has set out a target to grow revenue to $80 billion by 2030 as it aims to bolster its investment in technologies and platforms....
From In-House at AstraZeneca to an E-Discovery Startup: New Fileread GC Discusses Major Career Move...
Law.com· 4 days agoThe latest: E-discovery startup Fileread, which announced in early May that it hired the head of...
Tango terminates USP1 inhibitor programme
Clinical Trials Arena via Yahoo Finance· 3 hours agoThe company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...
...Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal...
WROC Rochester· 2 days agoUnder the terms of the agreement, Nona Biosciences shall receive US$19 million upon completion...
AstraZeneca plans to build $1.5 billion manufacturing facility in Singapore
WSAU Wausau· 4 days ago(Reuters) -AstraZeneca said on Monday it plans to build a $1.5 billion manufacturing facility in...
AstraZeneca shares rise as pharma group unveils 2030 revenue target By Investing.com
Investing.com· 3 days agoU.K.-listed shares in AstraZeneca (LON:AZN) rose in morning trading on Tuesday after the...
AstraZeneca aims increase its annual revenue by 75% in its post-COVID era
Quartz· 3 days agoCambridge, U.K.-based pharmacuetical giant AstraZeneca announced an ambitious sales goal for the end of this decade, just as it pulls it COVID-19 vaccines off the shelves.
AstraZeneca to harness China's 'explosion' of innovation to boost cell therapy R&D
FierceBiotech· 3 days agoAstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy...